Dyne Therapeutics, Inc.DYNNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank71
3Y CAGR+32.9%
5Y CAGR-33.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+32.9%/yr
Annual compound
5Y CAGR
-33.1%/yr
Recent acceleration
Percentile
P71
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 41.55% |
| 2024 | 33.52% |
| 2023 | 47.63% |
| 2022 | 17.68% |
| 2021 | 168.38% |
| 2020 | 309.42% |
| 2019 | 158.06% |
| 2018 | 0.00% |
| 2017 | 0.00% |
| 2016 | 0.00% |